NASDAQ Framework: Celldex Therapeutics Inc.
Biopharmaceutical company developing antibody-based therapeutics 1.
1: Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is... View Source
Celldex Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative immunotherapy technologies and targeted biologics. The company is dedicated to exploring mast cell biology and creating transformative therapeutics for patients with unmet medical needs, particularly in inflammatory, allergic, autoimmune, and other severe diseases. Its pipeline includes promising drug candidates such as Barzolvolimab, a monoclonal antibody targeting the KIT receptor, which is currently undergoing global Phase 3 trials for Chronic Spontaneous Urticaria. Celldex also engages in clinical trials for various cancers and other conditions, leveraging its robust in-house capabilities and strategic collaborations to advance its proprietary antibody programs 2345.
2: Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is... View Source3: Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527. View Source4: Celldex Therapeutics, Inc. engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ. View Source5: Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey. View Source
UNKNOWN
The available facts do not provide specific information regarding whether the founders of Celldex Therapeutics Inc. are still leading the company or are heavily involved in its operations. The facts mention the company's focus, pipeline, and some insider trading activities but do not address the current involvement of the founders [fERROR]UNKNOWN
The available facts do not provide specific information regarding whether the founders of Celldex Therapeutics Inc. are still leading the company or are heavily involved in its operations. The facts mention the company's focus, pipeline, and some insider trading activities but do not address the current involvement of the founders [fERROR][fERROR]UNKNOWN
The available facts do not provide specific information regarding whether the founders of Celldex Therapeutics Inc. are still leading the company or are heavily involved in its operations. The facts mention the company's focus, pipeline, and some insider trading activities but do not address the current involvement of the founders [fERROR][fERROR][fERROR]UNKNOWN
The available facts do not provide specific information regarding whether the founders of Celldex Therapeutics Inc. are still leading the company or are heavily involved in its operations. The facts mention the company's focus, pipeline, and some insider trading activities but do not address the current involvement of the founders [fERROR][fERROR][fERROR][fERROR]UNKNOWN
The available facts do not provide specific information regarding whether the founders of Celldex Therapeutics Inc. are still leading the company or are heavily involved in its operations. The facts mention the company's focus, pipeline, and some insider trading activities but do not address the current involvement of the founders [fERROR][fERROR][fERROR][fERROR].
The available facts do not provide specific information regarding whether the founders of Celldex Therapeutics Inc. are still leading the company or are heavily involved in its operations. The facts mention the company's focus, pipeline, and some insider trading activities but do not address the current involvement of the founders [fERROR]UNKNOWN
The available facts do not provide specific information regarding whether the founders of Celldex Therapeutics Inc. are still leading the company or are heavily involved in its operations. The facts mention the company's focus, pipeline, and some insider trading activities but do not address the current involvement of the founders [fERROR][fERROR]UNKNOWN
The available facts do not provide specific information regarding whether the founders of Celldex Therapeutics Inc. are still leading the company or are heavily involved in its operations. The facts mention the company's focus, pipeline, and some insider trading activities but do not address the current involvement of the founders [fERROR][fERROR][fERROR]UNKNOWN
The available facts do not provide specific information regarding whether the founders of Celldex Therapeutics Inc. are still leading the company or are heavily involved in its operations. The facts mention the company's focus, pipeline, and some insider trading activities but do not address the current involvement of the founders [fERROR][fERROR][fERROR][fERROR]UNKNOWN
The available facts do not provide specific information regarding whether the founders of Celldex Therapeutics Inc. are still leading the company or are heavily involved in its operations. The facts mention the company's focus, pipeline, and some insider trading activities but do not address the current involvement of the founders [fERROR][fERROR][fERROR][fERROR].
HIGH RISK
Celldex Therapeutics Inc. faces significant financial challenges. The company experienced a substantial decline in revenue growth, approximately -83.87% as of March 31, 2024, which is well below the average growth rate of its peers in the Health Care sector 6. Additionally, Celldex's net margin is notably poor at -21030.77%, indicating severe difficulties in achieving profitability 7. These financial indicators, combined with the company's negative Return on Equity (ROE) of -5.18% 8 and Return on Assets (ROA) of -4.92% 9, suggest that Celldex is struggling with effective cost control and asset utilization. Therefore, the company's financial situation is classified as HIGH RISK.
Celldex Therapeutics Inc. faces significant financial challenges. The company experienced a substantial decline in revenue growth, approximately -83.87% as of March 31, 2024, which is well below the average growth rate of its peers in the Health Care sector 6. Additionally, Celldex's net margin is notably poor at -21030.77%, indicating severe difficulties in achieving profitability 7. These financial indicators, combined with the company's negative Return on Equity (ROE) of -5.18% 8 and Return on Assets (ROA) of -4.92% 9, suggest that Celldex is struggling with effective cost control and asset utilization. Therefore, the company's financial situation is classified as HIGH RISK.
6: Negative Revenue Trend: Examining Celldex Therapeutics's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -83.87% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers. View Source7: Net Margin: Celldex Therapeutics's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -21030.77%, the company may encounter challenges in effective cost control. View Source8: Return on Equity (ROE): Celldex Therapeutics's ROE excels beyond industry benchmarks, reaching -5.18%. This signifies robust financial management and efficient use of shareholder equity capital. View Source9: Return on Assets (ROA): Celldex Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of -4.92%, the company demonstrates effective utilization of assets and strong financial performance. View Source
10: Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria GlobeNewswire Jul 16, 2024 12:01pm Celldex Therapeutics to Present at Jefferies Healthcare Conference GlobeNewswire Jun 4, 2024 8:01pm Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024 GlobeNewswire Jun 2, 2024 1:01pm Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis GlobeNewswire May 15, 2024 12:01pm Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update GlobeNewswire May 6, 2024 8:01pm Celldex Therapeutics shares surge as lead asset shows promise in two skin conditions MarketWatch Nov 6, 2023 1:15pm View Source11: Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria View Source
Celldex Therapeutics Inc.'s product roadmap and expansion strategy for 2024 through 2026 are centered around advancing its innovative immunotherapy technologies and targeted biologics. A key focus is the global Phase 3 program for Barzolvolimab, a monoclonal antibody targeting the KIT receptor, in patients with Chronic Spontaneous Urticaria 1213. Additionally, the company is conducting Phase 2 studies of Barzolvolimab in Prurigo Nodularis and has completed enrollment in a Phase 2 study for Chronic Inducible Urticaria 1415. Celldex's strategic plan includes leveraging its robust in-house capabilities and strategic collaborations to advance its proprietary antibody programs, aiming to address unmet medical needs in inflammatory, allergic, autoimmune, and other severe diseases 1617.
12: Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria GlobeNewswire Jul 16, 2024 12:01pm Celldex Therapeutics to Present at Jefferies Healthcare Conference GlobeNewswire Jun 4, 2024 8:01pm Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024 GlobeNewswire Jun 2, 2024 1:01pm Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis GlobeNewswire May 15, 2024 12:01pm Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update GlobeNewswire May 6, 2024 8:01pm Celldex Therapeutics shares surge as lead asset shows promise in two skin conditions MarketWatch Nov 6, 2023 1:15pm View Source13: Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria View Source14: Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis View Source15: Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria View Source16: Driven by our deep and longstanding experience developing antibody-based immunotherapies, Celldex’s proprietary antibody programs and technologies are supported by robust in-house capabilities, enabling the optimized discovery and development of innovative scientific programs. View Source17: Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey. View Source